Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Clinical Trials01:16

Clinical Trials

10.1K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.1K
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

1.9K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
1.9K
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

963
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
963

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

The relationship between cerebellar functional connectivity alterations and hand dexterity impairment in multiple sclerosis.

Journal of neurology·2026
Same author

Anti-CD20 Therapies in Pediatric Acquired Demyelinating Syndromes: Evidence Across MS, AQP4-IgG-Positive NMOSD and MOGAD.

CNS drugs·2026
Same author

T1W/T2W Ratio to Assess Brain Microstructural Damage in Multiple Sclerosis: A Multicenter Study.

AJNR. American journal of neuroradiology·2026
Same author

An automated quantitative report for multiple sclerosis using only 3D T2-fluid-attenuated inversion recovery MRI.

Neuroradiology·2026
Same author

Structural MRI signature of late- versus adult-onset multiple sclerosis: a multiparametric study.

Journal of neurology·2026
Same author

Lifespan Modeling of Choroid Plexus Volume in Multiple Sclerosis and Its Dynamic Associations With Clinical, MRI, and HLA Susceptibility.

Neurology(R) neuroimmunology & neuroinflammation·2026
Same journal

Spatially defined microenvironmental niches are associated with clinical outcome and tumor ecosystem diversity in head and neck cancer.

Med (New York, N.Y.)·2026
Same journal

AI-driven therapeutic antisense oligonucleotide for processing-deficient progeroid laminopathies.

Med (New York, N.Y.)·2026
Same journal

Advanced cholangiocarcinoma in 2025: Therapeutic sequencing and global implementation.

Med (New York, N.Y.)·2026
Same journal

Atlas of human brain imaging-derived phenotypes and disease risk.

Med (New York, N.Y.)·2026
Same journal

Withdrawal effects following treatment discontinuation: A blind spot in evidence-based medicine.

Med (New York, N.Y.)·2026
Same journal

Rethinking parenteral nutrition as supportive therapy for neonatal sepsis.

Med (New York, N.Y.)·2026
Ver todos los artículos relacionados

Video Experimental Relacionado

Updated: Jan 13, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.5K

Esclerosis múltiple progresiva: Seis ensayos a seguir

Maria A Rocca1, Paolo Preziosa1, Massimo Filippi2

  • 1Neuroimaging Research Unit, Division of Neuroscience, IRCCS San Raffaele Scientific Institute, Milan, Italy; Neurology Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy; Vita-Salute San Raffaele University, Milan, Italy.

Med (New York, N.Y.)
|January 10, 2026
PubMed
Resumen
Este resumen es generado por máquina.

Las nuevas terapias para la esclerosis múltiple progresiva (EMp) se dirigen a la inflamación del SNC. Seis ensayos investigan inhibidores de la tirosina quinasa de Bruton, bloqueo de CD40-CD40L y células CAR-T para tratar la patología de la microglía y las células B.

Palabras clave:
esclerosis múltiple progresivaterapias emergentesinhibidores de BTKcélulas CAR-Tinflamación del SNCensayos clínicosmicroglíacélulas B

Más Videos Relacionados

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.7K

Videos de Experimentos Relacionados

Last Updated: Jan 13, 2026

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
08:11

Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis

Published on: November 14, 2016

11.5K
The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test MSPT: An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

58.6K
Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla
08:51

Magnetic Resonance Imaging of Multiple Sclerosis at 7.0 Tesla

Published on: February 19, 2021

9.7K

Área de la Ciencia:

  • Neuroinmunología
  • Terapéutica Clínica
  • Medicina Traslacional

Sus antecedentes:

  • La esclerosis múltiple progresiva (EMp) se caracteriza por inflamación del SNC, que impulsa la progresión de la enfermedad independientemente de la actividad de las recaídas.
  • Los paradigmas de tratamiento actuales para la EMp son limitados, lo que representa una necesidad clínica insatisfecha significativa.
  • Las estrategias terapéuticas emergentes tienen como objetivo abordar la inmunopatología subyacente de la EMp.

Objetivo del estudio:

  • Revisar las terapias emergentes dirigidas a la inflamación compartimentada en el SNC en la esclerosis múltiple progresiva (EMp).
  • Destacar los ensayos clínicos fundamentales que evalúan agentes inmunomoduladores novedosos para la EMp.
  • Analizar el potencial de estas terapias para redefinir el tratamiento de la EMp al dirigirse a vías celulares clave.

Principales métodos:

  • Revisión de seis ensayos clínicos fundamentales para la esclerosis múltiple progresiva (EMp).
  • Enfoque en terapias que incluyen inhibidores de la tirosina quinasa de Bruton (BTK), bloqueo de CD40-CD40L y células T con CAR dirigidas a CD19.
  • Análisis de los mecanismos de acción dirigidos a la patología de la microglía y las células B.

Principales resultados:

  • Varias clases de terapias novedosas están en investigación para la EMp.
  • Estos agentes se dirigen a distintas vías inmunitarias implicadas en la neuroinflamación y la neurodegeneración.
  • Los datos preliminares sugieren potencial para la modificación de la enfermedad en formas progresivas de EM.

Conclusiones:

  • Las terapias emergentes dirigidas a la inflamación del SNC prometen tratar la esclerosis múltiple progresiva (EMp).
  • La modulación de la actividad de la microglía y las células B representa una estrategia clave para futuros tratamientos de la EMp.
  • Estos avances pueden mejorar significativamente los resultados para los pacientes con necesidades clínicas insatisfechas en la EMp.